The cost-effectiveness of preventing AIDS-related opportunistic infections

JAMA

Volumn 279, Issue 2, 1998, Pages 130-135

  Freedberg, Kenneth A ^a,b,c   Scharfstein, Julie A ^a,c   Seage III, George R ^b   Losina, Elena ^b   Weinstein, Milton C ^c   Craven, Donald E ^a,b   Paltiel, A David ^d  

^a BOSTON MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; AZITHROMYCIN; CLARITHROMYCIN; COTRIMOXAZOLE; FLUCONAZOLE; GANCICLOVIR; RIFABUTIN; SULFAMETHOXAZOLE; TRIMETHOPRIM SULFATE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; DRUG COST; DRUG MIXTURE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOXOPLASMOSIS;

EID: 0032515391     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.2.130     Document Type: Article

References (48)

1. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of an international panel. JAMA. 1997;277:1962-1969.
2. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cells counts from 200 to 500 per cubic millimeter. N Engl J Med. 1996;335:1081-1090.
3. Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter: North American HIV Working Party. N Engl J Med. 1995;333:1662-1669.
4. Kaplan JE, Masur H, Holmes KK, et al. USPHS/ IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: an overview. Clin Infect Dis. 1995; 21(suppl):512-531.
5. Ioannidis JP, Cappelleri JC, Skolnik PR, Lair J, Sacks HS. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med. 1996;156:177-188.
6. Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med. 1995;332: 693-699.
7. Nightingale SD, Cameron DW, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med. 1993;329:828-833.
8. Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med. 1996;335:392-398.
9. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med. 1996;335:384-391.
10. Powderly WG, Finkelstein D, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med. 1995;332: 700-705.
11. Spector SA, McKinley GF, Jacob P, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med. 1996; 334:1491-1497.
12. Drug Topics Red Book. Montvale, NJ: Medical Economics; 1996.
13. Doyle A,Jefferys R, Kelly J. State AIDS Drug Assistance Programs: A National Status Report on Access. Washington, DC, and New York, NY: National Alliance of State and Territorial AIDS Directors and AIDS Treatment Data Network; July 10, 1997.
14. Gold MR, Siegel JE, Russel LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
15. Berk ML, Mafeo C, Schur CI. Research Design and Analysis Objectives, AIDS Cost and Services Utilization Survey (ACSUS) Report No. 1. Rockville, Md: Agency for Health Care Policy and Research; 1993. AHCPR publication 93-0019.
16. Phair J, Munoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N Engl J Med. 1990;322:161-165.
17. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992;41(RR-17):1-19.
18. Multicenter AIDS Cohort Study (MACS) Public Dataset: Release P04. Springfield, Va: National Technical Information Service; 1995.
19. Enger C, Graham N, Peng Y, et al. Survival from early, intermediate, and late stages of HIV infection. JAMA. 1996;275:1329-1334.
20. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Renaldo CR Jr, for the Multicenter AIDS Cohort Study. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol. 1987;126:310-318.
21. Miettinen OS. Estimability and estimation in casereferent studies. Am J Epidemiol. 1976;103:226-235.
22. Laird NM, Ware JH. Random effects model for longitudinal data. Biometrics. 1983;38:963-974.
23. Miller DK, Homan SM. Determining transition probabilities. Med Decis Making. 1994;14:52-58.
24. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making. 1983;3:419-458.
25. Brosgart C, Graig C, Hillman D, et al. Final results from a randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of CMV retinal and gastrointestinal mucosal disease. In: Program and abstracts of the XI International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract Th.B.301.
26. Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: AIDS Clinical Trials Group Protocol 021. N Engl J Med. 1992;327:1842-1848.
27. AIDS Cost and Services Utilization Survey: Public Use Tapes 4 and 5. Springfield, Va: National Technical Information Service; 1994. No. PB94-189891.
28. Hospital AIDS/HIV Survey. Washington, DC: The National Public Health and Hospital Institute; 1991.
29. Centers for Disease Control and Prevention. AIDS cases and annual rates per 100,000 population, by metropolitan area 500,000 or more population. HIV/AIDS Surveill Rep. February 1993:7-8.
30. Bureau of the Census. Statistical Abstract of the United States. 115th ed. Washington, DC: US Bureau of the Census; 1995.
31. Torrance GW. Social preferences for health states: an empirical evaluation of three measurement techniques. Socioecon Planning Sci. 1976;10: 128-136.
32. Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med. 1996;124:633-642.
33. Finkelstein DM, Williams PL, Molenberghs G, et al. Patterns of opportunistic infections in patients with HIV infection. J Acquir Immune Defic Syndr. 1996;12:38-45.
34. Sande MA, Carpenter CCJ, Cobbs CG, et al. Antiretroviral therapy for adult HIV-infeeted patients: recommendations from a state-of-the-art conference. JAMA. 1993;270:2583-2589.
35. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734-739.
36. Cantor SB. Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment. Med Decis Making. 1994;14:259-265.
37. 3: a cost-effectiveness analysis. J Acquir Immune Defic Syndr. 1991;4:521-531.
38. Freedberg KA, Hardy WD, Holzman RS, Tosteson ANA, Craven DE. Validating literature-based models with direct clinical trial results: the cost-effectiveness of secondary prophylaxis for PCP in AIDS patients. Med Decis Making. 1996;16:29-35.
39. Castellano AR, Nettleman MD. Cost and benefit of secondary prophylaxis for Pneumocystis carinii pneumonia. JAMA. 1991;266:820-824.
40. Freedberg KA, Cohen CJ, BarberTW. Preventing Mycobacterium avium complex infection in patients with AIDS: a cost-effectiveness analysis. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15:275-282.
41. Scharfstein JA, Paltiel AD, Freedberg KA. The cost-effectiveness of fluconazole prophylaxis for systemic fungal infections in patients with AIDS. Med Decis Making. 1997;17:483-489.
42. Rose DN, Sacks HS. Cost-effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: oral ganciclovir and CMV polymerase chain reaction testing. AIDS. 1997;11:883-887.
43. Paltiel AD, Freedberg KA. Cost-effectiveness of preventing CMV disease in AIDS patients. Interfaces. In press.
44. Robbins GK, Cotton DJ. Cost-effectiveness of ganciclovir for prevention of CMV retinitis. In: Program and abstracts of the 4th Conference on Retro viruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 296.
45. Walmsley S, Mazzulli T, Shankaran P, Krajden M. Predictive value of a single CMV PCR and subsequent development of end organ disease. In: Program and abstracts of the 4th Conference on Retro viruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 702.
46. 3 following antiretroviral therapy for HIV-1. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 656.
47. Jacobson MA, Kramer F, Pavan PR, Owens S, Pollard R, and the NIAID ACTG Protocol 266 Team. Failure of highly active antiretroviral therapy to prevent CMV retinitis despite marked CD4 count increase. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 726.
48. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep. 1997;46(RR-12):1-46.